Abstract
Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder in children which manifests with hyperactivity, impulsivity, and/or inattention. Several drugs are used in treatment of ADHD. Stimulants, atomoxetine, anti-depressants, and bupropion are common medications used in the treatment of ADHD. Stimulants are widely used as the first line treatment in children with ADHD. Their mechanism of action is the release of dopamine and norepinephrine in central nervous system. Methylphenidate is the most common stimulant used for the treatment of ADHD. Methylphenidate significantly reduces ADHD symptoms in children both at home and school and improves their social skills. Methylphenidate is safe in healthy children and has shown to have no cardiac side effects in these patients. Other medications include: Atomoxetine, Amphetamines, Clonidine, Melatonin, and anti-depressants. Effects, side effects, and mechanism of action these drugs have been discussed in this paper.
Keywords: Attention-deficit hyperactivity disorder, Methylphenidate, Atomoxetine, Amphetamines.
Current Pharmaceutical Design
Title:Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects
Volume: 22 Issue: 5
Author(s): Javad Golmirzaei, Hamidreza Mahboobi, Maryam Yazdanparast, Gohar Mushtaq, Mohammad A. Kamal and Enayatollah Hamzei
Affiliation:
Keywords: Attention-deficit hyperactivity disorder, Methylphenidate, Atomoxetine, Amphetamines.
Abstract: Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder in children which manifests with hyperactivity, impulsivity, and/or inattention. Several drugs are used in treatment of ADHD. Stimulants, atomoxetine, anti-depressants, and bupropion are common medications used in the treatment of ADHD. Stimulants are widely used as the first line treatment in children with ADHD. Their mechanism of action is the release of dopamine and norepinephrine in central nervous system. Methylphenidate is the most common stimulant used for the treatment of ADHD. Methylphenidate significantly reduces ADHD symptoms in children both at home and school and improves their social skills. Methylphenidate is safe in healthy children and has shown to have no cardiac side effects in these patients. Other medications include: Atomoxetine, Amphetamines, Clonidine, Melatonin, and anti-depressants. Effects, side effects, and mechanism of action these drugs have been discussed in this paper.
Export Options
About this article
Cite this article as:
Golmirzaei Javad, Mahboobi Hamidreza, Yazdanparast Maryam, Mushtaq Gohar, Kamal A. Mohammad and Hamzei Enayatollah, Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects, Current Pharmaceutical Design 2016; 22 (5) . https://dx.doi.org/10.2174/1381612822666151124235816
DOI https://dx.doi.org/10.2174/1381612822666151124235816 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Can Modulating Inflammatory Response be a Good Strategy to Treat Neuropathic Pain?
Current Pharmaceutical Design TRP Channels in the Digestive System
Current Pharmaceutical Biotechnology Cognitive Dysfunction in Depression: Lessons Learned from Animal Models
CNS & Neurological Disorders - Drug Targets Converting Peptides into Drug Leads by Lipidation
Current Medicinal Chemistry PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration
Current Alzheimer Research Impact of Early Life Stress on the Pathogenesis of Mental Disorders: Relation to Brain Oxidative Stress
Current Pharmaceutical Design Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Therapeutic Approach for Neuronal Disease by Regulating Reninangiotensin System
Current Hypertension Reviews Connecting the Brain and New Drug Targets for Schizophrenia
Current Pharmaceutical Design Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research Neurovascular Changes in Acute, sub-Acute and Chronic Mouse Models of Parkinson’s Disease
Current Neurovascular Research The Plasticity of the 7TMR Signaling Machinery and the Search for Pharmacological Selectivity
Current Pharmaceutical Design NPY and Cardiac Diseases
Current Topics in Medicinal Chemistry Serotonin Receptors, Type 4: A New Hope?
Current Drug Targets Evidence for Altered LRP/RAGE Expression in Alzheimer Lesion Pathogenesis
Current Alzheimer Research Exploration of Umbelliferone Based Derivatives as Potent MAO Inhibitors: Dry vs. Wet Lab Evaluation
Current Topics in Medicinal Chemistry Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design VEGF Signaling Regulates Cofilin and the Arp2/3-complex within the Axonal Growth Cone
Current Neurovascular Research